Autopsy report · NCT00661921

A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus

“Program Development discontinued”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Amgen

Sponsor type

Industry

Conditions

Diabetes Mellitus

Interventions

AMG 108; Placebo

Participants

0

Trials that died the same way

• Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
  “Development discontinued” (84% match in meaning)
• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (71% match in meaning)
• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
  “Development program terminated.” (70% match in meaning)
• A Natural History Study of Aspartylglucosaminuria
  “Discontinued AGU development program” (66% match in meaning)
• A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
  “Compound development discontinued” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.